Slideshow
Findings of an exclusive Urology Times survey raise questions about the safety of urologic practice.
FDA Advisory Committee unanimously votes against talazoparib plus enzalutamide for mCRPC
FDA Advisory Committee finds evidence for UGN-102 inconclusive, cites uncertainty in benefit-risk
Pivotal trial launches of 64Cu-SAR-bisPSMA in BCR of prostate cancer
Meeting with FDA paves way for phase 3 trial of PT-112 in mCRPC
2 Commerce Drive
Cranbury, NJ 08512